iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum

Updated: Mar 15

DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond Venture (MADV) Virtual Spring Forum on Friday, March 25, 2022.


Dedicated to improving the management of neuropathic pain, iQure developed iQ‑007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in both neuropathic pain as well as epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.


“We are delighted to have been invited to present at this high-profile event,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “This presentation helps to expand our network to an even larger group of investors from the Mid-Atlantic region and enhances our company’s ongoing fund-raising efforts.”


Mid-Atlantic Diamond Ventures (MADV) is an independent organization that assists emerging, technology-based companies in their effort to build sustainable businesses by better positioning them for funding while increasing value at an early and crucial stage.


To date, over 400 Mid-Atlantic companies have presented at MADV and have raised more than $640 million. MADV is located at the Temple University Fox School of Business and is sponsored by prestigious service firms, major angel constituencies, as well as, local economic development groups.

31 views

Recent Posts

See All

Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth DELAWARE, April 07, 2022 ─iQure Pharma Inc. (iQure), a US-based global biotec